Monte Rosa Therapeutics swings to Q3 net income of $3.06 million from year-earlier loss

• Monte Rosa Therapeutics swung to third-quarter 2026 net income of $3.06 million from a year-earlier net loss of $27.08 million.
• Collaboration revenue rose year-over-year to $54.37 million, primarily driven by a $50 million milestone for Novartis’s Sjögren’s disease study initiation.
• Cash, cash equivalents, restricted cash and marketable securities totaled $582.6 million at September 30, expected to support operations into 2029.
• MRT-8102’s Phase 2 gout study is expected to begin in Q4 2026, with initial data anticipated in H2 2027.
• The Phase 2 MODeFIRe-1 prostate cancer study began dosing in August, with a clinical data update expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870666) on November 05, 2026, and is solely responsible for the information contained therein.